Newsroom
Strive to Deliver Breakthroughs
Cambridge, MA, Rotterdam, NL, Suzhou, CN - August 28, 2023 Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global ...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN— August 28, 2023 Harbour BioMed (the“Company”, HKEX: 02142) announced that the U.S. Foo...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – August 8, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – July 13, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – June 29, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View moreHBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour ...
View morePorustobart in combination of toripalimab showed promising anti-tumor activity Porustobart in combination of toripalimab showed acceptable safet...
View morePorustobart in combination with toripalimab showed promising anti-tumor activity in advanced high-grade neuroendocrine neoplasms (NENs) The ORR and DCR we...
View moreCAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or...
View moreCambridge, MA, Rotterdam, NL, Suzhou, CN – March 6, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more